Come up with a name for your new list and we'll add to it:
jCyte raised a round of funding on January 05, 2017. Investors include
California Institute of Regenerative Medicine.
jCyte is developing jCell, an effective stem cell therapy for retinitis pigmentosa (RP). It uses retinal progenitor cells (RPCs) to rescue diseased retinal cells and possibly regenerate new ones. This…